Age (N=479) |
|
|
16 – 25 |
192 |
40.3 |
26 – 35 |
190 |
39.7 |
36 – 45 |
62 |
12.9 |
46 – 55 |
25 |
5.2 |
56 – 65 |
9 |
1.9 |
66 – 75 |
1 |
0.2 |
Limited Gender Category (N=486) |
|
|
Man/Trans man |
373 |
76.8 |
Non-binary |
113 |
23.3 |
Testosterone Formulation (N=486)* |
|
|
Testosterone undecanoate (Reandron) |
358 |
73.7 |
Testosterone enanthate (Primoteston depot) |
38 |
7.8 |
Testosterone esters (Sustanon 250) |
10 |
2.1 |
Testosterone 1% gel (Testogel) |
62 |
12.8 |
Testosterone 2% gel (Testavan) |
10 |
2.1 |
Testosterone 5% cream (Androforte 5) |
11 |
2.3 |
Testosterone 2% cream (Androforte 2) |
1 |
0.2 |
Other |
3 |
0.6 |
Self-Reported Testosterone Dosage (N=486) |
|
|
Full dose |
430 |
87.7 |
Half dose |
33 |
6.8 |
Quarter dose |
9 |
1.9 |
Other (e.g., change in dosage) |
14 |
3.7 |
Self-reported Testosterone Blood Concentrations nmol/L (N=144) |
|
|
0.0 – 4.9 |
5 |
3.5 |
5.0 – 9.9 |
18 |
12.5 |
10.0 – 14.9 |
38 |
26.4 |
15.0 – 19.9 |
35 |
24.3 |
20.0 – 24.9 |
23 |
16.0 |
25.0 – 29.9 |
14 |
9.7 |
30.00+ |
11 |
7.6 |
Consistency of testosterone use (N=485) |
|
|
Consistent use since starting |
426 |
87.8 |
Regularly stop and start use |
10 |
2.1 |
Other (e.g., change in dosage or formulation) |
46 |
9.5 |
Unsure/Prefer not to say |
3 |
0.6 |